Immunotherapy and targeted therapy—the new roadmap in cancer treatment

Medicine has witnessed many discoveries in the last century. From the discovery of diphtheria anti-toxin leading to the first Nobel Prize in medicine awarded to Emil von Behring in 1901, to discovery of penicillin by Alexander Fleming, to treatment of HIV, there have been many breakthroughs over the years. This has been amply represented in the distribution of Nobel prizes in medicine and physiology over the years. Every era and every year depicting a breakthrough which has helped humanity in fighting ailments. If twentieth century was the antibiotics era, this century should be dubbed—the immunotherapy era, considering the difference it has already made in improving survival in cancer patients. In this context it would not be wrong to call the year 2018—the year of immunotherapy